Relay Therapeutics pricing
No price exists to publish because Dynamo is not sold. Relay develops its own medicines, and the partnerships it announces bring capability inward rather than licensing the platform out, such as the December 2023 agreement applying a partner's DNA encoded library screening alongside Dynamo against a GPCR target, announced without economics. There is nothing to buy, and the relationship on offer is investment or collaboration.
How Relay Therapeutics pricing works
- Pricing model
- Own clinical pipeline plus inbound capability partnerships. No platform license is sold.
As a listed company Relay files financial statements, program status and risk factors on a regular cadence, describing its own economics rather than a price anyone can apply. What a discovery collaboration would cost, and how rights would be split, are not published.
Relay Therapeutics pricing against its alternatives
Published prices for Relay Therapeutics and the products closest to it. Each figure is as the vendor publishes it, in its own currency and billing unit.
- RRelay TherapeuticsNot applicable
- IIambic TherapeuticsPartnership structured, no list pricing
- SSuperluminal MedicinesNo published price
- EEikon TherapeuticsNot applicable
- PPostEraNo published price
- VVariational AICustom project pricing
- RRecursionNot applicable
- AA-Alpha BioNo published price
- IIsomorphic LabsNot applicable
Relay Therapeutics pricing, answered
How much does Relay Therapeutics cost?
Relay Therapeutics does not publish a price. Relay develops its own medicines, and the partnerships it announces bring capability inward rather than licensing the platform out, such as the December 2023 agreement applying a partner's DNA encoded library screening alongside Dynamo against a GPCR target, announced without economics. There is nothing to buy, and the relationship on offer is investment or collaboration.